Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd. Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.
CSIR in partnership with Laxai Life Sciences has received regulatory approval to….
By DD News | Dated – June 11, 2021
CSIR-Laxai Life Sciences get DCGI approval for clinical trials Colchicine on Covid patients…
By The Hindu BusinessLine | Hyderabad | Dated – June 12, 2021